Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04434196 · ClinicalTrials.gov registry record · Phase 1
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 15
- Study locations
NCT04434196: Completed Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.
NCT04434196 is a Phase 1 study of Lymphoma, Non-Hodgkin that has completed, run by Celgene. The registered enrollment target is 16 participants, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04434196, a Phase 1 study of Lymphoma, Non-Hodgkin, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 15
- Study locations
Study Summary
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Primary Outcome
Number of subjects with a DLT
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG CC-99282
Study Locations (15)
Other
- Local Institution - 403 - Innsbruck
- Local Institution - 401 - Salzburg
- Local Institution - 402 - Vienna
- Local Institution - 302 - Barcelona
- Local Institution - 306 - Madrid
- Local Institution - 301 - Madrid
- Local Institution - 303 - Salamanca
- Local Institution - 305 - Valencia
Massachusetts
- Local Institution - 106 - Boston
Ohio
- Local Institution - 104 - Columbus
Oregon
- Local Institution - 101 - Portland
Texas
- Local Institution - 107 - Dallas
Ontario
- Local Institution - 201 - Toronto
Quebec
- Local Institution - 202 - Montreal
Navarre
- Local Institution - 304 - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 1 |
What the finished NCT04434196 record still lists
NCT04434196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT04434196 lists 15 locations in 8 states (Other, Massachusetts, Ohio).
Frequently Asked Questions
What is clinical trial NCT04434196 about?
NCT04434196 is a clinical study titled "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
What is the current status of trial NCT04434196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-12-21. Estimated completion is 2024-05-21.
What conditions does trial NCT04434196 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT04434196?
The interventions under investigation include: Obinutuzumab (DRUG), CC-99282 (DRUG).
Who is sponsoring clinical trial NCT04434196?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04434196 being conducted?
This trial has 15 study locations across Massachusetts, Ohio, Oregon, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04434196's enrollment target sits among peer trials
16 55th of 58 higher than 4 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI